TESARO, Inc. (NASDAQ:TSRO) – Oppenheimer Holdings issued their FY2021 earnings per share (EPS) estimates for TESARO in a research report issued to clients and investors on Wednesday. Oppenheimer Holdings analyst L. Cann expects that the biopharmaceutical company will earn $14.60 per share for the year. Oppenheimer Holdings has a “Buy” rating and a $199.00 price target on the stock.

A number of other research analysts have also issued reports on TSRO. Gabelli initiated coverage on shares of TESARO in a research note on Friday, July 7th. They issued a “buy” rating and a $175.00 target price on the stock. Janney Montgomery Scott reiterated a “neutral” rating on shares of TESARO in a research note on Friday, July 14th. ValuEngine lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub lowered shares of TESARO from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Finally, Credit Suisse Group set a $198.00 target price on shares of TESARO and gave the company a “buy” rating in a research note on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $166.10.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/30/tesaro-inc-tsro-expected-to-earn-fy2021-earnings-of-14-60-per-share.html.

Shares of TESARO (TSRO) traded up 0.29% during midday trading on Monday, hitting $115.95. 168,732 shares of the stock were exchanged. TESARO has a 12-month low of $106.64 and a 12-month high of $192.94. The stock’s 50 day moving average is $118.70 and its 200 day moving average is $131.65. The firm’s market cap is $6.28 billion.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the prior year, the firm earned ($1.28) EPS. The business’s quarterly revenue was down 17.6% compared to the same quarter last year.

In other news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Martin H. Jr. Huber sold 592 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at $823,439.80. The disclosure for this sale can be found here. Insiders have sold a total of 35,692 shares of company stock valued at $4,628,976 over the last ninety days. 34.60% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the company. Exane Derivatives bought a new position in TESARO during the 3rd quarter valued at about $106,000. Botty Investors LLC bought a new position in TESARO during the 2nd quarter valued at about $140,000. Nordea Investment Management AB bought a new position in TESARO during the 2nd quarter valued at about $167,000. Oppenheimer Asset Management Inc. lifted its holdings in TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,430 shares during the last quarter. Finally, BB&T Securities LLC bought a new position in TESARO during the 2nd quarter valued at about $222,000.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.